ClinicalTrials.gg
CompletedNCT00096993Updated Jun 10, 2015Results posted

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 2 interventional study of Placebo and Gemcitabine in Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by Genentech, Inc.. Completed at 41 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Ovarian Neoplasms by Hoffmann-La Roche — none open to participants now, 3 under way, none of them phase 3. Ovarian Neoplasms · Hoffmann-La Roche.

Enrollment
12th of 30
131 · median 100
Started
2005
with 2 others
Phase 2
12 of 35
none open now
Registered
3rd of 35
by date

Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 2, and was the 3rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of pertuzumab in combination with gemcitabine relative to placebo in combination with gemcitabine in subjects with advanced ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy.

03

Conditions studied

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Omnitarg
  • Cancer
  • Platinum-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age >= 18 years
  • Advanced, documented ovarian, primary peritoneal, or fallopian tube carcinoma
  • Representative tumor specimens in paraffin blocks or at least 12 unstained slides with an associated pathology report, obtained at any time prior to entry of study for evaluation of activation
  • with at least one lesion that can be accurately measured in at least one dimension (longest dimension recorded), Or:
  • Clinically or radiologically detectable disease (e.g., ascites, peritoneal deposits, mesenteric thickening or lesions that do not fulfill for measurable disease)
  • Platinum-resistant or carcinoma
  • >= 12 weeks
  • performance status 0 or 1
  • >= 50%, as determined by ECHO
  • Use of an effective means of (for women of )
  • Clinical laboratory test results: Granulocyte count >= 1500/uL; count >= 75,000/uL; >= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbopoeitin [Aranesp(R)] is permitted); Serum \<= 1.5 the ; Alkaline phosphatase, , and ALT \<= 2.5 ULN (AST, ALT \<= 5 ULN for subjects with liver ); Serum creatinine \<= 1.5 ULN; (INR) \<= 1.5 and activated partial thromboplastin time (aPTT) \<= 1.5 ULN (except for subjects receiving anti-coagulation therapy)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with gemcitabine
  • Two or more prior regimens for the treatment of platinum-resistant disease
  • Two or more non-platinum-containing regimens for the treatment of platinum-sensitive disease
  • Prior treatment with experimental anti-cancer agents within 4 weeks prior to Day 1 (the day the first study treatment infusions are administered)
  • Prior treatment with pathway inhibitors (e.g., Herceptin(R) [trastuzumab], Iressa(R) [gefitinib], Tarceva\<TM> [erlotinib hydrochloride], cetuximab, GW572016)
  • History or clinical evidence of central nervous system or
  • Uncontrolled hypercalcemia ( > 11.5 mg/dL)
  • Prior exposure of > 360 mg/m\^2 doxorubicin or liposomal doxorubicin, > 120 mg/m\^2 mitoxantrone, or > 90 mg/m\^2 idarubicin
  • History of other within 5 years of Day 1, except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, basal or squamous cell skin cancer
  • History of serious systemic disease, unstable angina, myocardial infarction within 6 months prior to Day 1 of treatment, symptoms of CHF, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia [i.e., atrial fibrillation, paroxysmal supraventricular tachycardia] are eligible)
  • Known infection
  • Pregnancy or lactation
  • Major surgery or significant traumatic injury within 3 weeks prior to Day 1 of treatment
  • Inability to comply with study and follow-up procedures
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
131 participants (actual)

Study arms

  • Placebo comparator
    Placebo + gemcitabine

    Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m\^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).

    Drug: Placebo · Drug: Gemcitabine

  • Active comparator
    Pertuzumab + gemcitabine

    Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m\^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles

    Drug: Gemcitabine · Drug: Pertuzumab

Interventions

  • DrugPlacebo

    Placebo was provided as a single-use formulation for infusion.

  • Gemcitabine was provided as a solution for infusion.

    Also known as: Gemzar

  • Pertuzumab was provided as a single-use formulation for infusion.

    Also known as: rhuMAb 2C4

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from the first day of treatment (Cycle 1, Day 1) to the time of documented disease progression or death, whichever occurred first. Disease progression was assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR) was defined as disappearance of all target lesions; Partial Response (PR) was defined as \>=30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.

    Time frame: Baseline to the end of the study (up to 1 year)

Secondary outcomes

  1. Percentage of Participants With an Objective Response

    An objective response was defined as a complete or partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors (RECIST). A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.

    Time frame: Baseline to the end of the study (up to 1 year)

  2. Duration of the Objective Response

    Duration of the objective response was defined as the time from the initial response to disease progression or death from any cause.

    Time frame: Baseline to the end of the study (up to 1 year)

  3. Percentage of Participants Free From Disease Progression at 4 Months

    Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Baseline to Month 4

  4. Duration of Survival

    Duration of survival was defined as the time from randomization until death from any cause.

    Time frame: Baseline to the end of the study (up to 1 year)

07

Results

Posted Jun 10, 2015

Participant flow

Participant flow — Overall Study
MilestonePlacebo + GemcitabinePertuzumab + Gemcitabine
Started6665
Completed10
Not completed6565
Withdrew: Death10
Withdrew: Disease progression5653
Withdrew: Adverse event28
Withdrew: Subject's decision31
Withdrew: Physician decision21
Withdrew: Non-compliance01
Withdrew: Other unspecified11

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from the first day of treatment (Cycle 1, Day 1) to the time of documented disease progression or death, whichever occurred first. Disease progression was assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR) was defined as disappearance of all target lesions; Partial Response (PR) was defined as \>=30% decrease in the sum of the longest diameter of target lesions and Overall Response (OR) = CR + PR.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Median · months
Progression-free Survival
monthsPlacebo + GemcitabinePertuzumab + Gemcitabine
Progression-free Survival2.6 (1.4 to 3.9)2.9 (2.6 to 4.4)
SecondaryPercentage of Participants With an Objective Response

An objective response was defined as a complete or partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors (RECIST). A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsPlacebo + GemcitabinePertuzumab + Gemcitabine
Percentage of Participants With an Objective Response4.613.8
SecondaryDuration of the Objective Response

Duration of the objective response was defined as the time from the initial response to disease progression or death from any cause.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Median · months
Duration of the Objective Response
monthsPlacebo + GemcitabinePertuzumab + Gemcitabine
Duration of the Objective ResponseNA (4.1 to NA)6.9 (4.1 to 7.4)
SecondaryPercentage of Participants Free From Disease Progression at 4 Months

Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Baseline to Month 4
Reported as:
Number · percentage of participants
Percentage of Participants Free From Disease Progression at 4 Months
percentage of participantsPlacebo + GemcitabinePertuzumab + Gemcitabine
Percentage of Participants Free From Disease Progression at 4 Months37.347.6
SecondaryDuration of Survival

Duration of survival was defined as the time from randomization until death from any cause.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Median · months
Duration of Survival
monthsPlacebo + GemcitabinePertuzumab + Gemcitabine
Duration of Survival13.1 (10.5 to 15.5)13.0 (9.6 to 18.5)

Adverse events

Collected over All adverse events were collected from the beginning of study treatment until 30 days after discontinuation of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Gemcitabine—40/65 (61.5%)65/65 (100%)
Pertuzumab + Gemcitabine—23/65 (35.4%)65/65 (100%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventPlacebo + GemcitabinePertuzumab + Gemcitabine
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders8/652/65
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders1/654/65
VOMITINGGastrointestinal disorders3/651/65
INTESTINAL OBSTRUCTIONGastrointestinal disorders3/650/65
RENAL FAILURE ACUTERenal and urinary disorders3/651/65
DEHYDRATIONMetabolism and nutrition disorders3/651/65
ILEUSGastrointestinal disorders2/651/65
ABDOMINAL PAINGastrointestinal disorders0/652/65
NAUSEAGastrointestinal disorders2/650/65
DYSPNOEARespiratory, thoracic and mediastinal disorders2/652/65
Most frequent other events
Showing 10 of 107
Most frequent other events
EventPlacebo + GemcitabinePertuzumab + Gemcitabine
FATIGUEGeneral disorders50/6551/65
NAUSEAGastrointestinal disorders47/6549/65
DIARRHOEAGastrointestinal disorders39/6544/65
CONSTIPATIONGastrointestinal disorders40/6513/65
ANAEMIABlood and lymphatic system disorders39/6531/65
VOMITINGGastrointestinal disorders33/6532/65
NEUTROPENIABlood and lymphatic system disorders29/6532/65
OEDEMA PERIPHERALGeneral disorders28/6520/65
BACK PAINMusculoskeletal and connective tissue disorders18/6527/65
ABDOMINAL PAINGastrointestinal disorders26/6522/65

Baseline characteristics

Safety population: All participants who received any amount of study treatment.

Age, Continuous
Age, Continuous(years)Placebo + GemcitabinePertuzumab + GemcitabineTotal
Mean59.7 ± 11.9457.8 ± 10.7958.7 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + GemcitabinePertuzumab + GemcitabineTotal
Female6565130
Male000
08

Study locations

41 sites
  • Univ. of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Comprehensive Cancer Institute
    Huntsville, Alabama 35801, United States
  • Northwest Alabama Cancer Center
    Muscle Shoals, Alabama 35661, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Alta Bates Comp. Cancer Ctr
    Berkeley, California 94704, United States
  • California Cancer Crae, Inc
    Greenbrae, California 94904, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • Southern California Permanente Medical Group (Kaiser)
    San Diego, California 92120, United States
  • Sharp Healthcare
    San Diego, California 92123, United States
  • Norwalk Medical Group
    Norwalk, Connecticut 06856, United States
  • Hematology Oncology, P.C.
    Stamford, Connecticut 06902, United States
  • Integrated Community Oncology Network
    Jacksonville, Florida 32256, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • Memorial Health Univ. Med. Ctr.
    Savannah, Georgia 31404, United States
  • St. Luke's Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • North Idaho Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • University Of Chicago
    Chicago, Illinois 60637, United States
  • Carle Clinic Association
    Urbana, Illinois 61801, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • St. Vincent Hospital
    Indianapolis, Indiana 46260, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Franklin Square Hospital Center
    Baltimore, Maryland 21237, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Wayne State Univ. Barbara Ann Karmanos Cancer Inst.
    Detroit, Michigan 48201, United States
  • Center for Cancer and Hematologic Disease
    Cherry Hill, New Jersey 08003, United States
  • Cooper Health System
    Voorhees, New Jersey 08043, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Ohio State University College of Medicaine
    Columbus, Ohio 43210, United States
  • Pelvic Surgery Assoc.
    Columbus, Ohio 43222, United States
  • Oklahoma Univ. Medical Center
    Oklahoma City, Oklahoma 73104, United States
  • Corvallis Clinic
    Corvallis, Oregon 97330, United States
  • Kaiser Permanente Northwest Division
    Portland, Oregon 97227, United States
  • Womens and Infants Hospital
    Providence, Rhode Island 02905, United States
  • Northern Virginia Pelvic Surgery Assoc.
    Annandale, Virginia 22003, United States
  • Carilion Gyn/Onc
    Roanoke, Virginia 24014, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 7 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2004
First posted
Nov 18, 2004
Start
Jan 2005
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results first posted
Jun 10, 2015
Last update
Jun 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00096993
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2004
Start date
Jan 2005
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Jun 10, 2015
Last update
Jun 10, 2015

Study contacts

Virginia Patton, M.D.
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion